Cited by 151MicroRNA in disease regulationPlant Molecular Biology ResearchCancer-related molecular mechanisms research

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 22 of the 47 sources its claims cite were checked for support.

Toward the human cellular microRNAome

Open access

Published version of a preprint

Abstract

MicroRNAs are short RNAs that serve as regulators of gene expression and are essential components of normal development as well as modulators of disease. MicroRNAs generally act cell-autonomously, and thus their localization to specific cell types is needed to guide our understanding of microRNA activity. Current tissue-level data have caused considerable confusion, and comprehensive cell-level data do not yet exist. Here, we establish the landscape of human cell-specific microRNA expression. This project evaluated 8 billion small RNA-seq reads from 46 primary cell types, 42 cancer or immortalized cell lines, and 26 tissues. It identified both specific and ubiquitous patterns of expression that strongly correlate with adjacent superenhancer activity. Analysis of unaligned RNA reads uncovered 207 unknown minor strand (passenger) microRNAs of known microRNA loci and 495 novel putative microRNA loci. Although cancer cell lines generally recapitulated the expression patterns of matched primary cells, their isomiR sequence families exhibited increased disorder, suggesting DROSHA- and DICER1-dependent microRNA processing variability. Cell-specific patterns of microRNA expression were used to de-convolute variable cellular composition of colon and adipose tissue samples, highlighting one use of these cell-specific microRNA expression data. Characterization of cellular microRNA expression across a wide variety of cell types provides a new understanding of this critical regulatory RNA species.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This study establishes a human cell-specific microRNA expression landscape by analyzing small RNA-seq across primary cells, cancer/immortalized cell lines, and tissues. It identifies cell-restricted and ubiquitous microRNAs, links expression to superenhancers, reports 495 high-confidence putative novel microRNAs, and shows substantial isomiR diversity that differs between primary and cancer cells.

Key findings

  • Across 46 primary cell types, 42 cancer/immortalized cell lines, and 26 tissues, 2319 of 2546 known microRNAs (miRBase v21) were detected at ≥1 read per million microRNA reads in at least one sample; 320 microRNAs reached ≥1000 RPM in at least one of 46 normal cell types, and 94 (29%) were present in only a single cell class. Six microRNAs were present in all 46 cell types at ≥1000 RPM: miR-107, miR-103a-3p, miR-103b, miR-191-5p, miR-21-5p, and miR-92a-3p.
  • MicroRNA expression strongly correlated with adjacent superenhancer activity: expression was significantly higher when a superenhancer was within 40 kb of the microRNA locus (Wilcoxon rank-sum test, P < 2.2−16), and cell-type-restricted microRNAs matched cell-specific superenhancer activity.
  • Novel microRNA discovery from 1.2 billion unmapped reads yielded 21,338 miRDeep2 loci, which were refined to 495 highest-confidence putative novel microRNAs; 207 unassigned passenger microRNAs from known loci were also found. Validation included miRanalyzer overlap, Argonaute CLIP-seq evidence, PhyloP conservation, DICER1-knockout dependence, and PCR of nine novel microRNAs.
  • IsomiR analysis of 126 primary cell and 82 cancer/immortalized cell samples showed that the miRBase v21 canonical sequence was the most abundant isomiR in only 33% of primary-cell microRNAs, and 37% never had the canonical sequence as most abundant; cancer/immortalized cells had a ∼20% increase in disorder over primary cells (P < 0.005, Wilcoxon rank-sum test).

Methods

  • The study combined new small RNA-seq from 39 primary cell samples with public Sequence Read Archive/Array Express data, processing 694 samples through miRge and retaining 530 for analysis: 161 primary cell datasets (46 main cell types), 100 cancer/immortalized cell line datasets (42 cell lines), and 269 tissue datasets (26 tissues).
  • MicroRNA expression states were discretized with DEXUS; batch effects were addressed with RUV normalization and SVA; clustering used t-SNE. Cell-specific signatures were used with CIBERSORT to de-convolute adipose and colon tissue composition.
  • Novel microRNA detection used miRDeep2 and miRanalyzer on unmapped reads, followed by novoMiRank, PhyloP conservation, Argonaute CLIP-seq, DICER1-knockout data, and PCR validation. IsomiR families were analyzed for templated length variants, 5′ start variation, and nontemplated 3′ nucleotide additions.

Limitations

  • The paper states that much data came from public sources across different platforms and sequencing methods, creating technical variation; extensive normalization was used, but technical factors still drive some variation and clustering. Some cell types had few to no replicates, it is unknown how well cultured cells match in vivo cells, and many cell types (hepatocytes, neutrophils, pneumocytes) were unavailable.
  • The paper states that the 495 putative novel microRNAs are not definitive, many are likely false positives, and in vivo proof was beyond scope; requiring multiple evidence sources may also have lost true positives.
  • Evident from the text: superenhancer correlations are not proof of superenhancer activity on adjacent microRNAs, and the authors caution that the activity of these superenhancers on adjacent genes and microRNAs is generally unknown.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1101/gr.222067.117

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

22 of 47 cited sources checked · 11 supported · 0 flagged · accuracy not yet measured

Show all 95 claims

  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 32
47 of 47
  • The paper relies on this without support.

    MicroRNAs generally act cell-autonomously.

    “MicroRNAs generally act cell-autonomously, and thus their localization to specific cell types is needed to guide our understanding of microRNA activity.”
  • The paper relies on this without support.

    Current tissue-level microRNA data have caused considerable confusion.

    “Current tissue-level data have caused considerable confusion, and comprehensive cell-level data do not yet exist.”
  • The paper relies on this without support.

    Small RNA-seq has become a robust method to fully characterize known microRNAs, capture complete isomiR families, and identify novel microRNAs.

    “Small RNA-seq has become a robust method to fully characterize known microRNAs, capture complete isomiR families, and identify novel microRNAs.”
  • The paper relies on this without support.

    The microRNA community has been forthright in depositing RNA-seq data into central public repositories.

    “The microRNA community has been forthright in depositing RNA-seq data into central public repositories.”
  • The paper relies on this without support.

    Immortalized and cancer-derived cell lines are frequent surrogates for primary cells in understanding biologic pathways.

    “Immortalized and cancer-derived cell lines are frequent surrogates for primary cells in understanding biologic pathways.”
  • The paper relies on this without support.

    The extent of differences in microRNA expression between immortalized/cancer cell lines and primary cells is unknown.

    “However, the extent of differences in microRNA expression between these cell lines and primary cells is unknown.”
  • The paper relies on this without support.

    The cross-contamination of H1264 with H157 is of no consequence for the way data from this cell line were used.

    “However, in the context of the way data from this cell line were used, that distinction is of no consequence here.”
  • The paper relies on this without support.

    There are more microRNAs to be discovered in rare cell types and in developmental stages that have not been assessed.

    “It is likely that there are more microRNAs to be discovered in rare cell types and in developmental stages that have not been assessed.”
8 of 8

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Nonendothelial cell-type count differs for JHU_ID_23828

    Minor

    The figure caption gives 29 nonendothelial cell types for the comparison, while the Results give 30.

  • Percentage of candidates found in more than 50 samples is incorrect

    Minor

    Using the stated total of 25,218 putative microRNAs, 394 is 1.56%, not 0.7%.

    Reported 0.7 · recomputed 1.562376

  • Percentage of candidates found in individual samples is incorrect

    Minor

    Of the 25,218 putative microRNAs, 18,480 is 73.28%, not 65%.

    Reported 65 · recomputed 73.28099

  • Ago input count changes from 105 to 108

    Minor

    The Methods first identify 105 Ago-precipitated RNA reads, then say 108 Ago reads were processed in miRDeep2.

  • Primary-cell data set count changes from 161 to 162

    Minor

    The Results report 161 primary-cell RNA-seq data sets, whereas the Methods say 162 primary-cell runs were collapsed into the same 46 cell types.

  • Concluding cell-type count conflicts with the reported primary-cell coverage

    Minor

    The conclusion attributes the expression patterns to 42 cell types, but the study reports 46 primary cell types; 42 is elsewhere the count of cancer or immortalized cell lines.

6 of 6

Citations

Cites

Flagged first, then by citations

Show all 60 references

Research works printed but not linked: 1

  1. 2008, Visualizing data using t-SNE, Mach Learn Res, 9, 2579

Cited by

Sorted by citations

Items 101–151 of 151

Metadata

Authors
McCall, M. N., Kim, M.-S., Adil, M., Patil, A. H., Lu, Y., Mitchell, C. J., Leal-Rojas, P., Xu, J., Kumar, M., Dawson, V. L., Dawson, T. M., Baras, A. S., Rosenberg, A. Z., Arking, D. E., Burns, K. H., Pandey, A., & Halushka, M. K.
Affiliations
  • University of Rochester Medicine (US)
  • Johns Hopkins University (US)
  • B.S. Abdur Rahman Crescent Institute of Science & Technology (IN)
  • Ginkgo Bioworks, Inc. (United States) (US)
Venue
Genome Research
Published
2017-09-06
Volume
27
Issue
10
Pages
1769-1781
ISSN
  • 1088-9051 (ISSN-L)
  • 1549-5469
OpenAlex
W2951861059
Cited by
151
References
60
Citations by year
2026: 9 · 2025: 13 · 2024: 8 · 2023: 17 · 2022: 17 · 2021: 19 · 2020: 19 · 2019: 20 · 2018: 26 · 2017: 3
Type
posted content
Language
en
Open access
Locations
  • Genome Research (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Omeka S (Universidad de La Frontera) (submittedVersion, cc-by-nc-nd)
Funders
  • American Heart Association (13GRNT16420015)
  • National Institutes of Health
  • Cancer Center Support (P30CA016087)
  • Laura and Isaac Perlmutter Cancer Center
  • NCI's Clinical Proteomic Tumor Analysis Consortium
  • NIH (U24CA160036, U24CA210985)
  • National Fund for Scientific and Technological Development, FONDECYT (1151008, MSCRFII-0429, MSCRFII-0125, 2013-MSCRF-0054, 2014-MSCRF-0665)
  • NIH/NINDS (NS67525, NS37388)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Plant Molecular Biology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
microRNA, human cell types, cancer cell lines, super-enhancers, Drosha, DICER1, small RNA sequencing, colon tissue, adipose tissue, gene expression regulation
MeSH terms
Adult, Cell Line, Transformed, Humans, Male, Organ Specificity, RNA Processing, Post-Transcriptional, MicroRNAs, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review